Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MANTICO: Monoclonal Antibodies for COVID-19 Outpatients
NCT05205759Phase 3Terminated
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Dec 2021
- Primary completion
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bamlanivimab, etesevimab, sotrovimab in coronavirus disease 2019 (COVID-19), sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Started Dec 2021; status: terminated.
02
Drugs
bamlanivimabetesevimabsotrovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05205759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05205759.